Vainchtein L - Search Results

1

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.

Joerger M, Huitema AD, Boot H, Cats A, Doodeman VD, Smits PH, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny TD, Beijnen JH, Schellens JH. Joerger M, et al. Among authors: vainchtein l. Cancer Chemother Pharmacol. 2015 Apr;75(4):763-72. doi: 10.1007/s00280-015-2698-7. Epub 2015 Feb 13. Cancer Chemother Pharmacol. 2015. PMID: 25677447

2

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.

Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH. Joerger M, et al. Among authors: vainchtein ld. Cancer Chemother Pharmacol. 2012 Jan;69(1):25-33. doi: 10.1007/s00280-011-1670-4. Epub 2011 May 18. Cancer Chemother Pharmacol. 2012. PMID: 21590444

3

Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors.

Oostendorp RL, Witteveen PO, Schwartz B, Vainchtein LD, Schot M, Nol A, Rosing H, Beijnen JH, Voest EE, Schellens JH. Oostendorp RL, et al. Among authors: vainchtein ld. Invest New Drugs. 2010 Apr;28(2):163-70. doi: 10.1007/s10637-009-9244-6. Epub 2009 Apr 30. Invest New Drugs. 2010. PMID: 19404582 Clinical Trial.

4

A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.

Vainchtein LD, Rosing H, Schellens JH, Beijnen JH. Vainchtein LD, et al. Biomed Chromatogr. 2010 Apr;24(4):374-86. doi: 10.1002/bmc.1302. Biomed Chromatogr. 2010. PMID: 19650151

5

Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry.

Vainchtein LD, Rosing H, Thijssen B, Schellens JH, Beijnen JH. Vainchtein LD, et al. Rapid Commun Mass Spectrom. 2007;21(14):2312-22. doi: 10.1002/rcm.3096. Rapid Commun Mass Spectrom. 2007. PMID: 17577879

6

Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.

Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, Beijnen JH, Schellens JH, Schinkel AH. Vlaming ML, et al. Among authors: vainchtein ld. J Pharmacol Exp Ther. 2006 Jul;318(1):319-27. doi: 10.1124/jpet.106.101774. Epub 2006 Apr 12. J Pharmacol Exp Ther. 2006. PMID: 16611851 Free article.

7

Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer.

Vainchtein LD, Rosing H, Mirejovsky D, Lenaz L, Schellens JH, Beijnen JH. Vainchtein LD, et al. J Pharm Biomed Anal. 2007 Jan 4;43(1):285-92. doi: 10.1016/j.jpba.2006.06.044. Epub 2006 Aug 22. J Pharm Biomed Anal. 2007. PMID: 16920321

8

Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry.

Vainchtein LD, Rosing H, Maier A, Fiebig HH, Schellens JH, Beijnen JH. Vainchtein LD, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):261-6. doi: 10.1016/j.jchromb.2007.06.006. Epub 2007 Jun 22. J Chromatogr B Analyt Technol Biomed Life Sci. 2007. PMID: 17631060

9

A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry.

Vainchtein LD, Thijssen B, Stokvis E, Rosing H, Schellens JH, Beijnen JH. Vainchtein LD, et al. Biomed Chromatogr. 2006 Jan;20(1):139-48. doi: 10.1002/bmc.544. Biomed Chromatogr. 2006. PMID: 16041788

10

Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin given intravesically.

Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, Schellens JH, Beijnen JH. Vainchtein LD, et al. Rapid Commun Mass Spectrom. 2008;22(4):462-70. doi: 10.1002/rcm.3387. Rapid Commun Mass Spectrom. 2008. PMID: 18231986

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters